Literature DB >> 29229836

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.

Yapeng Su1,2, Wei Wei3,4,5, Lidia Robert6, Min Xue1,2, Jennifer Tsoi4, Angel Garcia-Diaz6, Blanca Homet Moreno6,7, Jungwoo Kim1,2, Rachel H Ng1,2, Jihoon W Lee1,2, Richard C Koya8, Begonya Comin-Anduix5,8, Thomas G Graeber4,5,9, Antoni Ribas10,5,6,8, James R Heath3,2,5.   

Abstract

Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lead to therapy resistance and escape from immune control before establishing acquired resistance genetically. We used genome-wide transcriptomics and single-cell phenotyping to explore the response kinetics to BRAF inhibition for a panel of patient-derived BRAFV600 -mutant melanoma cell lines. A subset of plastic cell lines, which followed a trajectory covering multiple known cell state transitions, provided models for more detailed biophysical investigations. Markov modeling revealed that the cell state transitions were reversible and mediated by both Lamarckian induction and nongenetic Darwinian selection of drug-tolerant states. Single-cell functional proteomics revealed activation of certain signaling networks shortly after BRAF inhibition, and before the appearance of drug-resistant phenotypes. Drug targeting those networks, in combination with BRAF inhibition, halted the adaptive transition and led to prolonged growth inhibition in multiple patient-derived cell lines.

Entities:  

Keywords:  Markov chain model; adaptive resistance; cell state transition; melanoma; single-cell analysis

Mesh:

Substances:

Year:  2017        PMID: 29229836      PMCID: PMC5748184          DOI: 10.1073/pnas.1712064115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  28 in total

1.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

2.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.

Authors:  David J Konieczkowski; Cory M Johannessen; Omar Abudayyeh; Jong Wook Kim; Zachary A Cooper; Adriano Piris; Dennie T Frederick; Michal Barzily-Rokni; Ravid Straussman; Rizwan Haq; David E Fisher; Jill P Mesirov; William C Hahn; Keith T Flaherty; Jennifer A Wargo; Pablo Tamayo; Levi A Garraway
Journal:  Cancer Discov       Date:  2014-04-25       Impact factor: 39.397

Review 3.  The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.

Authors:  Yong Lin; Lang Bai; Wenjie Chen; Shanling Xu
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

4.  The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Authors:  Rachel Ramsdale; Robert N Jorissen; Frederic Z Li; Sheren Al-Obaidi; Teresa Ward; Karen E Sheppard; Patricia E Bukczynska; Richard J Young; Samantha E Boyle; Mark Shackleton; Gideon Bollag; Georgina V Long; Eugene Tulchinsky; Helen Rizos; Richard B Pearson; Grant A McArthur; Amardeep S Dhillon; Petranel T Ferrao
Journal:  Sci Signal       Date:  2015-08-18       Impact factor: 8.192

5.  viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia.

Authors:  El-ad David Amir; Kara L Davis; Michelle D Tadmor; Erin F Simonds; Jacob H Levine; Sean C Bendall; Daniel K Shenfeld; Smita Krishnaswamy; Garry P Nolan; Dana Pe'er
Journal:  Nat Biotechnol       Date:  2013-05-19       Impact factor: 54.908

6.  Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation.

Authors:  Hyun-Mo Shin; Min-Hee Kim; Byung Hak Kim; Sang-Hun Jung; Yeong Shik Kim; Hye Ji Park; Jin Tae Hong; Kyung Rak Min; Youngsoo Kim
Journal:  FEBS Lett       Date:  2004-07-30       Impact factor: 4.124

7.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

8.  Nonequilibrium population dynamics of phenotype conversion of cancer cells.

Authors:  Joseph Xu Zhou; Angela Oliveira Pisco; Hong Qian; Sui Huang
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

9.  JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma.

Authors:  Bjoern Titz; Anastasia Lomova; Allison Le; Willy Hugo; Xiangju Kong; Johanna Ten Hoeve; Michael Friedman; Hubing Shi; Gatien Moriceau; Chunying Song; Aayoung Hong; Mohammad Atefi; Richard Li; Evangelia Komisopoulou; Antoni Ribas; Roger S Lo; Thomas G Graeber
Journal:  Cell Discov       Date:  2016-09-06       Impact factor: 10.849

10.  Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.

Authors:  Mohammad Fallahi-Sichani; Verena Becker; Benjamin Izar; Gregory J Baker; Jia-Ren Lin; Sarah A Boswell; Parin Shah; Asaf Rotem; Levi A Garraway; Peter K Sorger
Journal:  Mol Syst Biol       Date:  2017-01-09       Impact factor: 11.429

View more
  67 in total

Review 1.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

2.  Gene Networks with Transcriptional Bursting Recapitulate Rare Transient Coordinated High Expression States in Cancer.

Authors:  Lea Schuh; Michael Saint-Antoine; Eric M Sanford; Benjamin L Emert; Abhyudai Singh; Carsten Marr; Arjun Raj; Yogesh Goyal
Journal:  Cell Syst       Date:  2020-04-22       Impact factor: 10.304

Review 3.  A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.

Authors:  James T Yurkovich; Qiang Tian; Nathan D Price; Leroy Hood
Journal:  Nat Rev Clin Oncol       Date:  2019-10-16       Impact factor: 66.675

4.  Drug persistence - from antibiotics to cancer therapies.

Authors:  Karl Kochanowski; Leanna Morinishi; Steven Altschuler; Lani Wu
Journal:  Curr Opin Syst Biol       Date:  2018-03-31

Review 5.  Polytherapy and Targeted Cancer Drug Resistance.

Authors:  Nilanjana Chatterjee; Trever G Bivona
Journal:  Trends Cancer       Date:  2019-02-26

6.  Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer.

Authors:  Alexandre F Aissa; Abul B M M K Islam; Majd M Ariss; Cammille C Go; Alexandra E Rader; Ryan D Conrardy; Alexa M Gajda; Carlota Rubio-Perez; Klara Valyi-Nagy; Mary Pasquinelli; Lawrence E Feldman; Stefan J Green; Nuria Lopez-Bigas; Maxim V Frolov; Elizaveta V Benevolenskaya
Journal:  Nat Commun       Date:  2021-03-12       Impact factor: 14.919

Review 7.  Deep Profiling of Cellular Heterogeneity by Emerging Single-Cell Proteomic Technologies.

Authors:  Liwei Yang; Justin George; Jun Wang
Journal:  Proteomics       Date:  2019-12-02       Impact factor: 3.984

8.  Loss of TET2 Affects Proliferation and Drug Sensitivity through Altered Dynamics of Cell-State Transitions.

Authors:  Leanna Morinishi; Karl Kochanowski; Ross L Levine; Lani F Wu; Steven J Altschuler
Journal:  Cell Syst       Date:  2020-07-02       Impact factor: 10.304

Review 9.  The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer.

Authors:  Ravi Salgia; Prakash Kulkarni
Journal:  Trends Cancer       Date:  2018-02-03

10.  Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.

Authors:  Marie R Webster; Mitchell E Fane; Gretchen M Alicea; Subhasree Basu; Andrew V Kossenkov; Gloria E Marino; Stephen M Douglass; Amanpreet Kaur; Brett L Ecker; Keerthana Gnanapradeepan; Abibatou Ndoye; Curtis Kugel; Alexander Valiga; Jessica Palmer; Qin Liu; Xiaowei Xu; Jessicamarie Morris; Xiangfan Yin; Hong Wu; Wei Xu; Cathy Zheng; Giorgos C Karakousis; Ravi K Amaravadi; Tara C Mitchell; Filipe V Almeida; Min Xiao; Vito W Rebecca; Ying-Jie Wang; Lynn M Schuchter; Meenhard Herlyn; Maureen E Murphy; Ashani T Weeraratna
Journal:  Mol Cell       Date:  2019-12-11       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.